Forte Biosciences
FBRX
33 hedge funds and large institutions have $2.85M invested in Forte Biosciences in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 10 closing their positions.
5,850% more call options, than puts
Call options by funds: $119K | Put options by funds: $2K
0.1% less ownership
Funds ownership: 0.63% → 0.53% (-0.1%)
5% less capital invested
Capital invested by funds: $3.01M → $2.85M (-$152K)
15% less funds holding
Funds holding: 39 → 33 (-6)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$635K |
| 2 |
Renaissance Technologies
New York
|
+$289K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$237K |
| 4 |
Millennium Management
New York
|
+$91.6K |
| 5 |
OWP
Old Well Partners
Charlotte,
North Carolina
|
+$87.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$427K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$153K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$103K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$63.5K |
| 5 |
E
Ergoteles
New York
|
-$40.9K |
FBRX Hedge Fund Activity: Q3 2022 in Review
33 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2022, worth a combined $2.85M — down 5.1% from $3.01M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FBRX and 4 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Newtyn Management, opening a new position worth an estimated $635K. The largest seller was Morgan Stanley, cutting an estimated $427K.
- 33 institutional investors held Forte Biosciences (FBRX) as of Q3 2022, down from 39 in Q2 2022.
- Funds reported $2.85M of Forte Biosciences stock for Q3 2022, down 5.1% quarter-over-quarter.
- 4 funds opened new Forte Biosciences positions in Q3 2022 and 10 closed out, a net change of -6 holders.
- The largest Forte Biosciences buyer in Q3 2022 was Newtyn Management, an estimated $635K added.
- The largest Forte Biosciences seller in Q3 2022 was Morgan Stanley, an estimated $427K sold.
Based on aggregated 13F filings for Q3 2022.